ALK and anaplastic large cell lymphoma: The ALCL99 trial highlighted that while the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) is effective in ALK+ ALCL [8] the prognosis for systemic ALK- ALCL remains poor, with a five-year survival rate of only 30–50% [9].